Home/Pipeline/CAM2046

CAM2046

Undisclosed

PreclinicalActiveN/A

Key Facts

Indication

Undisclosed

Phase

Preclinical

Status

Active

Company

Camurus

About Camurus

Camurus is a fully integrated, commercial-stage biopharma focused on transforming chronic disease management through its proprietary FluidCrystal® long-acting injectable technology. The company has achieved commercial success with Buvidal® for opioid dependence and is advancing a diversified pipeline in pain, oncology, and endocrinology through a dual strategy of in-house development and strategic partnerships. With a validated platform, established commercial infrastructure in key markets, and a streamlined development model, Camurus is positioned to deliver significant value to patients, healthcare systems, and shareholders.

View full company profile

Therapeutic Areas

Central Nervous System Rare Diseases Endocrinology Oncology Supportive Care

Other Undisclosed Drugs

Drug	Company	Phase	Status
Preclinical ISAC 1	Bolt Biotherapeutics	Preclinical	Available for Partnering
Preclinical ISAC 2	Bolt Biotherapeutics	Preclinical	Available for Partnering
ART12.11	Artelo Biosciences	Preclinical	Active
Novel Vaccines	MSD	Development	Active
SLS-009	Seelos Therapeutics	Discovery	Research
Technosphere Platform (New Formulations)	MannKind	Discovery/Preclinical	Active R&D
Measovir®-based Prophylactic Vaccine (with Unither)	Oncovita	Research/Pre-clinical	Early-stage collaboration
Internal sdAb Discovery Program	NanoTag Biotechnologies	Discovery	Active
NB-701	Nerai Biosciences	Discovery	Active
Undisclosed Therapeutic Program(s)	Bright Cell	Clinical Trial (Phase unspecified)	Active
Biosimilars Pipeline	Intelligent Therapeutics	Pre-clinical/Development	Active
Proprietary Therapeutic Pipeline	Excelsior Sciences	Discovery	Active